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The Relative Safety and Efficacy
of Abciximab and Eptifibatide in Patients
Undergoing Primary Percutaneous Coronary Intervention
Insights From a Large Regional Registry
of Contemporary Percutaneous Coronary Intervention
Hitinder S. Gurm, MD,* Dean E. Smith, MS, PHD,* J. Stewart Collins, MD,*
David Share, MD, MPH,† Arthur Riba, MD,‡ Andrew J. Carter, MD,§ Thomas LaLonde, MD,
Eva Kline-Rogers, RN, MS,* Michael O’Donnell, MD,¶ Hameem Changezi, MD,#
Marcel Zughaib, MD,** Robert Safian, MD,†† Mauro Moscucci, MD,* for the Blue Cross Blue Shield
of Michigan Cardiovascular Consortium (BMC2)
Detroit, Dearborn, Kalamazoo, Ann Arbor, Grand Blanc, Southfield, and Royal Oak, Michigan
Objectives This study sought to assess whether the use of eptifibatide instead of abciximab is associated with a difference
in outcomes of patients undergoing primary percutaneous coronary intervention (PCI) for ST-segment elevation
myocardial infarction (STEMI).
Background Pooled data from randomized controlled trials suggest that the use of abciximab may be associated with a survival
advantage in patients undergoing primary PCI for acute STEMI. However, a large proportion of patients in the commu-
nity are treated with eptifibatide, an agent that shares some but not all pharmacological properties with abciximab.
Methods We evaluated the outcomes of 3,541 patients who underwent primary PCI for STEMI from October 2002 to July 2006
in a large regional consortium and who were treated with abciximab (n  729) or with eptifibatide (n  2,812).
Results There was no difference in the incidence of in-hospital death (4.1% with abciximab vs. 3.5% with eptifibatide,
p  0.39), recurrent myocardial infarction (0.8% vs. 1.2%, p  0.42), or stroke/transient ischemic attack (0.7%
vs. 0.6%, p  0.80). There was no difference in the need for blood transfusion (12.4% vs. 11.7%, p  0.61),
whereas there was a greater incidence of gastrointestinal bleeding with abciximab (4.8% vs. 2.8%, p  0.01).
In parsimonious risk-adjusted models, no significant difference between abciximab and eptifibatide was ob-
served with respect to any of the outcomes measures.
Conclusions Currently, eptifibatide is used as the adjunct antiplatelet agent in the majority of patients undergoing primary PCI.
There is no apparent difference in early outcomes of patients treated with eptifibatide compared with patients treated
with abciximab. (J Am Coll Cardiol 2008;51:529–35) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.09.053l
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referred reperfusion agent in ST-segment elevation myo-
ardial infarction (STEMI) (1). Data from randomized
ontrolled trials suggest that the adjunctive use of abciximab
ay be associated with a survival advantage in patients
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Relative Safety of Abciximab and Eptifibatide February 5, 2008:529–35ated with abciximab is still con-
troversial (4). Second, eptifiba-
tide or tirofiban, agents that
share some but not all pharma-
cological properties with abcix-
imab, are often less expensive
and more widely available in
many hospitals. Although the
only direct comparison between
tirofiban and abciximab sug-
gested that abciximab may be a
superior agent, that comparison
id not include STEMI patients (5). Given the widespread
se of small molecule glycoprotein (GP) IIb/IIIa inhibitors
n PCI, it is important to evaluate how often these agents
re used in patients undergoing primary PCI and whether
heir use is associated with any adverse clinical impact.
herefore, we evaluated the outcomes of patients undergo-
ng primary PCI in a regional consortium to analyze the
mpact of different GP IIb/IIIa inhibitors on clinical out-
omes of STEMI patients.
ethods
he study cohort for our analysis included patients under-
oing primary PCI in a large regional registry of contem-
orary PCI. The details of the registry and of the data
ollection process have been described elsewhere (6–10).
riefly, procedural data on all patients undergoing elective
nd nonelective PCI at the participating hospitals are
ollected using standardized data collection forms. Baseline
ata include clinical, demographic, procedural, and angio-
raphic characteristics as well as medications used before,
uring, and after the procedure, and in-hospital outcomes.
ll data elements have been prospectively defined, and the
rotocol was approved by the local institutional review
oard at each institution. The data were collected by a
edicated staff member and forwarded to the coordinating
enter. Medical records of all patients undergoing coronary
rtery bypass grafting (CABG) or of patients who died in
he hospital were reviewed to ensure data accuracy. A
urther 2% of cases were randomly selected for audit.
The study population for this analysis included patients
ho underwent primary PCI for STEMI between October
002 and July 2006 and who were treated with either
bciximab or eptifibatide. We excluded patients treated after
2 h of symptom onset, those transferred from another
nstitution, those undergoing rescue PCI after failed throm-
olysis, and patients treated with heparin alone or tirofiban.
All procedures were performed using standard coronary
ntervention technique. The choice of adjunct therapy was
t the discretion of the operating physician. The primary
nd point for this analysis was in-hospital death. Other end
oints evaluated included post-procedure transfusion and
n-hospital major adverse cardiovascular events defined as
he composite of death, myocardial infarction, stroke, all
Abbreviations
and Acronyms
CABG  coronary artery
bypass grafting
GP  glycoprotein
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarctionABG, or target lesion revascularization. In-hospital death bas defined as death for either cardiac or noncardiac cause;
lood transfusion was defined as any transfusion of blood
roduct regardless of the number of units transfused. Vas-
ular complication was defined as any of the following:
seudoaneurysm, arteriovenous fistula, femoral neuropathy,
etroperitoneal hematoma, hematoma at the access site
equiring transfusion/prolonged hospital stay or causing a
ecrease in hemoglobin 3.0 g/dl, or any access site
omplication requiring surgical repair.
tatistical analysis. Continuous variables are expressed as
ean  standard deviation, and discrete variables are
xpressed as frequency counts and percentages. The differ-
nces in discrete variables between groups were evaluated by
he chi-square test and Fisher exact test. Continuous vari-
bles were analyzed using the t test and Wilcoxon rank sum
est as needed. Univariate and multivariate logistic regres-
ion modeling was used to calculate unadjusted and
djusted odds of periprocedural events in association with
bciximab use.
To further adjust for the nonrandomized use of abciximab
nd for a possible selection bias in this cohort, a predictive
odel that adjusted for the propensity to receive abciximab was
lso developed (11). The probability or a propensity score of
eceiving abciximab was calculated using a nonparsimonious
ogistic regression model. The variables included in the model
ere age, gender, prior history of stroke, peripheral vascular
isease, hypertension, diabetes, congestive heart failure, prior
yocardial infarction, renal failure requiring dialysis, prior
astrointestinal bleeding, atrial fibrillation, prior revasculariza-
ion, chronic obstructive airway disease, serum creatinine and
emoglobin, extent of coronary artery disease, presence of
hrombus or calcification, pre-procedural medication use, left
entricular ejection fraction, and use of intra-aortic balloon
ump before the intervention. The propensity score was then
ncluded as an additional explanatory variable in the final
odels. Furthermore, we used Greedy matching techniques to
elect patients treated with eptifibatide as counterparts to
atients treated with abciximab by choosing the patient with
he nearest propensity score (12). In-hospital outcome was
hen compared within this propensity-matched cohort. Ran-
om effect models were fitted to control for clustering and
ariation by hospital. We also calculated the observed and
redicted mortality rates by the GP IIb/IIIa agent used
nd calculated the standardized mortality rates as previ-
usly described (9).
esults
total of 4,128 patients underwent primary PCI for
TEMI during the study period. Patients who were treated
ith tirofiban (n  4) or without a GP IIb/IIIa inhibitor
n  583) were excluded from the analysis. Thus, the study
ohort included 3,541 patients. The majority of patients
n  2,812) were treated with eptifibatide, whereas the
emainder (n  729) were treated with abciximab. The
roportion of patients treated with abciximab versus eptifi-
atide did not show any significant temporal trends (Fig. 1).
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February 5, 2008:529–35 Relative Safety of Abciximab and Eptifibatidehere was wide variation in the proportion of patients
reated with abciximab versus eptifibatide in the participat-
ng hospitals (Fig. 2).
Baseline demographic and clinical characteristics of the
opulation are shown in Table 1. Patients treated with
bciximab were more likely to have pre-existing renal failure
equiring dialysis and to have angiographically evident
hrombus. There was a slightly greater amount of contrast
sed in this group compared with those treated with
ptifibatide, and they were more likely to undergo multives-
el interventions. Patients treated with abciximab were more
ikely to receive pre-procedural clopidogrel and less likely to
Figure 1 Temporal Trends in Use of Abciximab Versus Eptifibat
There was no temporal trend in the relative use of abciximab versus eptifibatide. P
Figure 2 Proportion of Patients Treated With Abciximab Versus
Denominator reflects all patients undergoing primary percutaneous coronary interv
versus eptifibatide across the participating hospitals. Although all hospitals use epeceive pre-procedural beta-blockers. There was no differ-
nce in the other baseline demographics, comorbidities,
djunct medications, or procedural variables.
Clinical outcomes before hospital discharge are shown in
able 2. There was no difference in the angiographic
utcome, need for emergency bypass surgery, stroke, or
n-hospital mortality. There was no difference in vascular
omplications and need for transfusion, although the inci-
ence of gastrointestinal bleeding was higher among pa-
ients treated with abciximab (4.8% vs. 2.8%).
We evaluated the unadjusted mortality rate in multiple
ubgroups; elderly patients, women, patients in cardiogenic
Patients Undergoing Primary PCI
percutaneous coronary intervention.
fibatide in a Given Hospital
(PCI) at the hospital. There was wide variation in the relative use of abciximab
ide, abciximab use ranged from 0 to 56.7% of patients undergoing primary PCI.ide in
CI Epti
ention
tifibat
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Table 1 Baseline Demographics and Clinical Characteristicsof Patients Treated With Abciximab Versus Eptifibatide
Variable Eptifibatide (n  2,812) Abciximab (n  729) p Value
Demographic
Age, yrs (SD) 59.5 (13.1) 59.4 (12.7) 0.98
Age 60–69 yrs 592 (21.1) 166 (22.8) 0.31
Age 70–79 yrs 456 (16.2) 124 (17.0) 0.61
Age 80 yrs 236 (8.4) 46 (6.3) 0.06
Female 792 (28.2) 220 (30.2) 0.28
Current smoking 1,311 (46.6) 334 (45.8) 0.70
Lean (BMI 25 kg/m2) 603 (22.6) 156 (22.2) 0.81
Overweight (25  BMI 30 kg/m2) 1,038 (38.9) 290 (41.3) 0.26
Obese (BMI 30 kg/m2) 1,027 (38.5) 257 (36.6) 0.34
Historical
Hypertension 1,734 (61.7) 455 (62.4) 0.71
Prior myocardial infarction 626 (22.3) 157 (21.5) 0.67
Diabetes mellitus 589 (21.0) 166 (22.8) 0.28
Congestive heart failure 148 (5.3) 40 (5.5) 0.81
Extracardiac vascular disease 356 (12.7) 99 (13.6) 0.51
Renal failure requiring dialysis 12 (0.4) 9 (1.2) 0.01
Significant valve disease 56 (2.0) 21 (2.9) 0.14
Gastrointestinal bleeding 35 (1.2) 14 (1.9) 0.16
Atrial fibrillation 160 (5.7) 35 (4.8) 0.35
Cardiac arrest 58 (2.1) 7 (1.0) 0.05
Prior percutaneous coronary intervention 609 (21.6) 158 (21.7) 0.99
Prior coronary artery bypass grafting 189 (6.7) 44 (6.0) 0.51
Chronic obstructive airway disease 385 (13.7) 106 (14.5) 0.55
Laboratory
Baseline creatinine, mg/dl (SD) 1.11 (0.56) 1.17 (0.80) 0.05
Baseline creatinine 1.5 mg/dl 269 (9.9) 83 (11.7) 0.16
Anemia 475 (16.9) 126 (17.3) 0.80
Ejection fraction (SD) 46.0 (11.6) 45.6 (12.3) 0.83
Ejection fraction 50% 1,511 (53.7) 395 (54.2) 0.83
Procedural
Length of stay, days (median)* 5.2 5.8 0.0001*
Cardiac arrest 249 (8.9) 73 (10.0) 0.33
Cardiogenic shock 343 (12.2) 101 (13.9) 0.23
Ventricular tachycardia/fibrillation 216 (7.7) 66 (9.1) 0.22
Total contrast dose, ml (SD) 210 (84) 219 (89) 0.008
Exceeding MACD 202 (7.7) 66 (9.5) 0.12
Single-vessel disease (70%) 1,508 (53.6) 379 (52.0) 0.43
2-vessel disease (70%) 792 (28.2) 219 (30.0) 0.32
3-vessel disease (70%) 507 (18.0) 129 (17.7) 0.83
Intervention in 1 vessel 2,665 (94.8) 677 (92.9) 0.05
Intervention in 2 vessels 142 (5.1) 51 (7.0) 0.04
Intervention in 3 vessels 5 (0.2) 1 (0.1) 0.81
1 lesion 2,187 (77.8) 542 (74.4) 0.05
2 lesions 511 (18.2) 143 (19.6) 0.37
3 lesions 114 (4.1) 44 (6.0) 0.02
Left main stenosis (70%) 49 (1.7) 6 (0.8) 0.07
Restenotic lesion 161 (5.7) 42 (5.8) 0.97
Thrombus 1,590 (56.5) 487 (66.8) 0.0001
Calcification 360 (12.8) 100 (13.7) 0.51
Chronic total occlusion 53 (1.9) 11 (1.5) 0.50
Treatments
Pre-procedural intra-aortic balloon pump 8 (0.3) 1 (0.1) 0.70
Pre-procedural low-molecular-weight heparin 55 (2.0) 8 (1.1) 0.12
Pre-procedural unfractionated heparin 2,250 (80.0) 597 (81.9) 0.25Continued on next page
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atients with left anterior descending artery occlusion. No
ubgroups were identified in which 1 drug seemed to be
uperior to the other (data not shown).
There were no differences in any of the outcome variables
fter multivariate or propensity adjustment (Fig. 3). The model
sed for developing the propensity score had a c-statistic of 0.6.
he observed mortality in patients treated with either abcix-
mab or eptifibatide was lower than in patients treated without
GP IIb/IIIa inhibitor, and the standardized mortality rates
etween the 2 drug groups were remarkably similar (Fig. 4).
urthermore, in a propensity-matched cohort in which each
atient treated with abciximab was matched to a similar patient
reated with eptifibatide, no difference in any of the outcomes
as seen (Table 3).
iscussion
n our study, we evaluated the use of GP IIb/IIIa inhibitors
n patients undergoing PCI for STEMI in current clinical
ractice. Our data suggest that eptifibatide is the most
ommonly used GP IIb/IIIa inhibitor, and that the choice
f the GP IIb/IIIa inhibitor does not seem to influence
hort-term outcomes.
Continued
Table 1 Continued
Variable Eptifib
Treatments (cont.)
Pre-procedural aspirin use
Pre-procedural clopidogrel use
Pre-procedural lipid-lowering drug use
Pre-procedural angiotensin converting
enzyme inhibitor use
Pre-procedural beta-blocker use
Pre-procedural calcium channel blocker use
Pre-procedural diuretics use
Values are n (%) unless otherwise indicated. *For length of stay, the W
BMI  body mass index; MACD  maximal adjusted contrast dose;
Unadjusted Outcome of the Cohort Categorized
Table 2 Unadjusted Outcome of the Cohort
In-Hospital Outcomes Eptifi
Post-procedural TIMI flow grade 3 (%) success
Post-procedural stenosis (50%) success
Emergency coronary artery bypass surgery
Any coronary artery bypass surgery
(emergency and nonemergency)
Gastrointestinal bleeding
Vascular complications
Contrast nephropathy*
Post-procedure transfusion
Stroke
Myocardial infarction
Death
Revascularization (same site)
Major adverse cardiovascular event
Values are n (%). Major adverse cardiovascular event was defined as a
surgery, and revascularization. *The denominator reflects patients without pr
TIMI  Thrombolysis In Myocardial Infarction.Although mechanical reperfusion has emerged as the
herapy of choice for acute STEMI, the optimal pharma-
ological regimen for these patients has not been well
tudied. In contrast to studies of fibrinolytic agents, most
rials evaluating the safety and efficacy of GP IIb/IIIa
nhibitors in primary PCI for STEMI have been small
combined number of patients enrolled 5,000) and under-
owered to detect a mortality advantage. Within this small
ody of data, the majority of studies have evaluated the role
f abciximab when compared with placebo. In the meta-
nalysis performed by De Luca et al. (2), compared with
lacebo, the use of abciximab was associated with a signif-
cant reduction in 30-day mortality (2.4% vs. 3.4%, odds
atio 0.68, p  0.047) and long-term mortality (4.4% vs.
.2%). There was a commensurate reduction in re-
nfarction, whereas no difference in bleeding events was
oted. Recently, Montalescot et al. (13) reported a patient-
evel meta-analysis evaluating the impact of abciximab on
linical outcomes of patients undergoing stenting for pri-
ary PCI. Compared with placebo, the use of abciximab
as associated with a 37% reduction in the composite
azard of death or reinfarction at 3 years (hazard ratio 0.63,
5% confidence interval 0.45 to 0.88, p  0.008).
(n  2,812) Abciximab (n  729) p Value
(94.5) 694 (95.2) 0.47
(25.5) 290 (39.8) 0.001
(23.5) 192 (26.3) 0.10
(14.4) 106 (14.5) 0.94
(63.7) 431 (59.1) 0.02
(6.8) 62 (8.5) 0.11
(11.1) 99 (13.6) 0.07
n rank sum test was used.
standard deviation.
eatment
gorized by Treatment
(n  2,812) Abciximab (n  729) p Value
(92.2) 680 (93.5) 0.22
(95.1) 702 (96.4) 0.14
(1.0) 5 (0.7) 0.44
(3.3) 17 (2.3) 0.16
(2.8) 35 (4.8) 0.01
(4.5) 29 (4.0) 0.58
(5.8) 50 (7.5) 0.11
(11.7) 90 (12.4) 0.61
(0.6) 5 (0.7) 0.80
(1.2) 6 (0.8) 0.42
(3.5) 30 (4.1) 0.39
(1.1) 12 (1.6) 0.20
(8.8) 61 (8.4) 0.72
site of stroke, myocardial infarction, death, all coronary artery bypassatide
2,658
718
660
406
1,791
191
313by Tr
Cate
batide
2,575
2,663
28
94
79
125
150
328
17
33
97
30
247
compo
e-procedural renal failure requiring dialysis.
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Relative Safety of Abciximab and Eptifibatide February 5, 2008:529–35The experience with small-molecule GP IIb/IIIa inhibi-
ors is more limited and is restricted to smaller trials of
irofiban and 1 trial of eptifibatide. These trials were
esigned to compare upfront versus in-laboratory adminis-
ration of GP IIb/IIIa inhibitor and suggested better angio-
raphic outcomes with an early administration approach
13). A small angiographic study compared high-dose
irofiban with abciximab in 100 patients undergoing pri-
ary PCI. There was no difference in angiographic success,
picardial reperfusion, or left ventricular recovery between
he 2 groups (14). Although these data can be used to
upport potentially similar efficacy of tirofiban in primary
CI, none of the trials have evaluated the impact of the
Figure 3 Adjusted and Unadjusted In-Hospital Outcomes of Pat
The first plot (left) shows unadjusted odds ratios, the second plot (center) shows
ty-adjusted odds ratios. There was no difference in major cardiovascular complicat
and gastrointestinal bleeding were more common in patients treated with abcixima
propensity to receive abciximab. CABG  coronary artery bypass grafting; MACE 
Figure 4 SMR in Patients Undergoing Primary PCI
Based on Use of Eptifibatide and Abciximab
The observed mortality in patients treated with abciximab or eptifibatide was
lower than the predicted mortality. The standardized mortality rates (SMR) (a
ratio of observed mortality and predicted mortality) of patients treated with
abciximab and eptifibatide were similar. PCI  percutaneous coronary
intervention.uherapeutic switch on hard clinical end points. Thus, given
he lack of placebo-controlled trials, only indirect inferences
an be drawn about the safety and efficacy of small-molecule
P IIb/IIIa inhibitors in primary PCI.
In the only large-scale randomized trial evaluating the
elative efficacy of tirofiban and abciximab in a general patient
opulation, there was a reduction in ischemic events in patients
reated with abciximab that was predominantly seen in patients
ith acute coronary syndromes (5). However, patients with
cute STEMI were excluded from this trial.
Although purists would argue that abciximab is the only
gent that should be used in patients undergoing primary
CI for STEMI, market forces work against that. The
holesale acquisition cost of treating a 70-kg man with a
tandard dose of eptifibatide is $885.48, compared with
1,980.42 for abciximab (based on a 12-h infusion of
bciximab and an 18-h infusion of eptifibatide) (15). This
ost difference is the likely reason that many hospital
ormularies stock eptifibatide in preference to abciximab.
Our findings are thus important for several reasons. First,
hey provide an assessment of the current use of GP IIb/IIIa
nhibitors in contemporary clinical PCI practice for STEMI.
econd, we were unable to detect any difference in outcomes
ith the use of either agent. It can be estimated that given the
0-day outcomes of patients undergoing primary PCI, a trial
omparing eptifibatide and abciximab would need to enroll
ver 10,000 patients to show the noninferiority of one agent
hen compared with the other. The lack of major differences
n observational data, the cost of a trial of that size, and market
ealities suggest that such a trial is unlikely to be performed.
tudy limitations. Our findings are based on observational
ata that are not centrally adjudicated. Although the data were
nalyzed using risk adjustment and propensity analysis, we
annot exclude that we were unable to adjust for other
Treated With Abciximab Versus Eptifibatide
djusted odds ratios, and the third plot (right) shows risk-adjusted and propensi-
etween patients treated with abciximab and eptifibatide. Contrast nephropathy
this difference was not significant after risk adjustment or after adjusting for the
adverse cardiac events.ients
risk-a
ions b
b, but
majornknown factors that may influence outcome. Prior observa-
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February 5, 2008:529–35 Relative Safety of Abciximab and Eptifibatideional studies have detected differences in long-term but not in
hort-term outcomes of patients treated with GP IIb/IIIa
nhibitors versus those treated with heparin only (16). It is
ossible that the enhanced microcirculatory improvement
chieved with these drugs impacts long-term survival. Our
tudy cannot detect differences in long-term outcomes because
hese follow-up data are not collected in the registry.
onclusions
ptifibatide is the most commonly used GP IIb/IIIa inhib-
tor in patients undergoing primary PCI for acute STEMI
n our registry. Within the limits of the observational nature
f our study, there is no evidence to suggest that the use of
ptifibatide in lieu of abciximab is associated with worse
hort-term outcomes in this clinical setting. However, this
nding and the question of whether differences in use of
hese agents affect longer-term outcomes should be exam-
ned in larger prospective studies.
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1-226, 1500 East Medical Center Drive, Ann Arbor, Michigan
8103-0311. E-mail: Moscucci@umich.edu.
EFERENCES
1. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines
for the management of patients with ST-elevation myocardial
infarction—executive summary. A report of the American College of
Cardiology/American Heart Association Task Force on Practice
Guidelines (Writing Committee to Revise the 1999 Guidelines for the
Management of Patients With Acute Myocardial Infarction). J Am
Coll Cardiol 2004;44:671–719.
2. De Luca G, Suryapranata H, Stone GW, et al. Abciximab as
adjunctive therapy to reperfusion in acute ST-segment elevation
myocardial infarction: a meta-analysis of randomized trials. JAMA
2005;293:1759–65.
3. Raveendran G, Ting HH, Best PJ, et al. Eptifibatide vs abciximab as
In-Hospital Outcomes of the Propensity-Matched
Table 3 In-Hospital Outcomes of the Propen
In-Hospital Outcomes Eptifi
Post-procedural TIMI flow grade 3 (%) success
Post-procedural stenosis (50%) success
Emergency coronary artery bypass surgery
Any coronary artery bypass surgery
(emergency and nonemergency)
Gastrointestinal bleeding
Vascular complications
Contrast nephropathy*
Post-procedure transfusion
Stroke
Myocardial infarction
Death
Revascularization (same site)
Major adverse cardiovascular event†
Values are n (%). *The denominator reflects patients without pre-proced
defined as a composite of stroke, myocardial infarction, death, all cor
TIMI  Thrombolysis In Myocardial Infarction.adjunctive therapy during primary percutaneous coronary intervention
for acute myocardial infarction. Mayo Clin Proc 2007;82:196–202.4. Keeley EC, Boura JA, Grines CL. Comparison of primary and
facilitated percutaneous coronary interventions for ST-elevation myo-
cardial infarction: quantitative review of randomised trials. Lancet
2006;367:579–88.
5. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two
platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for
the prevention of ischemic events with percutaneous coronary revas-
cularization. N Engl J Med 2001;344:1888–94.
6. Kline-Rogers E, Share D, Bondie D, et al. Development of a
multicenter interventional cardiology database: the Blue Cross Blue
Shield of Michigan Cardiovascular Consortium (BMC2) experience.
J Interv Cardiol 2002;15:387–92.
7. Moscucci M, Kline-Rogers E, Share D, et al. Simple bedside additive
tool for prediction of in-hospital mortality after percutaneous coronary
interventions. Circulation 2001;104:263–8.
8. Moscucci M, Eagle KA, Share D, et al. Public reporting and case
selection for percutaneous coronary interventions: an analysis from two
large multicenter percutaneous coronary intervention databases. J Am
Coll Cardiol 2005;45:1759–65.
9. Moscucci M, Rogers EK, Montoye C, et al. Association of a
continuous quality improvement initiative with practice and outcome
variations of contemporary percutaneous coronary interventions. Cir-
culation 2006;113:814–22.
0. Moscucci M, O’Connor GT, Ellis SG, et al. Validation of risk
adjustment models for in-hospital percutaneous transluminal coronary
angioplasty mortality on an independent data set. J Am Coll Cardiol
1999;34:692–7.
1. D’Agostino RB Jr. Propensity score methods for bias reduction in the
comparison of a treatment to a non-randomized control group. Stat
Med 1998;17:2265–81.
2. Parson L. Reducing bias in a propensity score matched-pair sample
using Greedy matching techniques. Proceedings of the 26th Annual
SAS Users Group International Conference. Cary, NC: SAS
Institute, 2001:214 –26.
3. Montalescot G, Borentain M, Payot L, Collet JP, Thomas D.
Early vs late administration of glycoprotein IIb/IIIa inhibitors in
primary percutaneous coronary intervention of acute ST-segment
elevation myocardial infarction: a meta-analysis. JAMA 2004;292:
362– 6.
4. Danzi GB, Sesana M, Capuano C, Mauri L, Berra-Centurini P,
Baglini R. Comparison in patients having primary coronary angio-
plasty of abciximab versus tirofiban on recovery of left ventricular
function. Am J Cardiol 2004;94:35–9.
5. Red Book. Montvale NJ: Thomson Healthcare, 2007.
6. Berger JS, Brown DL. Association of glycoprotein IIb/IIIa inhibitors
and long-term survival following administration during percutaneous
ort Categorized by Treatment
atched Cohort Categorized by Treatment
(n  726) Abciximab (n  726) p Value
92.2) 677 (93.5) 0.35
95.6) 699 (96.4) 0.42
1.2) 5 (0.7) 0.28
3.7) 17 (2.3) 0.13
2.7) 35 (4.8) 0.04
3.6) 29 (3.9) 0.68
7.0) 49 (7.3) 0.83
11.9) 87 (11.9) 1
1.0) 5 (0.7) 0.56
1.2) 6 (0.8) 0.44
3.9) 29 (3.9) 0.89
1.38) 12 (1.65) 0.67
9.9) 60 (8.3) 0.27
nal failure requiring dialysis. †Major adverse cardiovascular event was
rtery bypass surgery, and revascularization.Coh
sity-M
batide
665 (
691 (
9 (
27 (
20 (
26 (
47 (
87 (
7 (
9 (
28 (
10 (
72 (
ural recoronary intervention for acute myocardial infarction. J Thromb
Thrombolysis 2006;21:229–34.
